BME:ROVIPharmaceuticals
Laboratorios Rovi (BME:ROVI) Stock Questioned As One Off Gain Lifts Reported Margins
Laboratorios Farmaceuticos Rovi (BME:ROVI) has released its Q2 2026 results with revenue of €191.7 million and net income of €75.0 million, set against trailing 12 month revenue of €773.1 million, net income of €185.2 million, and Basic EPS of €3.61 that reflects a 40% year over year earnings increase. Over recent quarters the company has seen revenue move from €159.7 million in Q2 2025 to €210.5 million in Q3 2025, €218.4 million in Q4 2025, €152.5 million in Q1 2026 and now €191.7 million...